The U.S. FDA released briefing documents ahead of the Dermatologic and Ophthalmic Drugs Advisory Committee meeting scheduled ...
Wall Street reacted with satisfaction to Genmab A/S phase III data proving that doctors can gain oomph against cancer by ...
Boston Scientific Corp. revised its guidance downwards for 2026, again, as it continues to have a challenging year. In ...
A perhaps unexpected theme of the first day of the European Society for Cell and Gene Therapy’s 2026 annual congress is how ...
The endocannabinoid system is a neuromodulatory network that plays a crucial role in brain development and neuronal signaling ...
Mycobacterium tuberculosis remains a leading cause of infectious disease-mediated death, with 10.8 million reported cases of ...
Already tagged with a potential “best-in-class” description by industry analysts on the back of positive phase III data unveiled earlier this year, Eli Lilly and Co.’s retatrutide turned up another ...
Astellas Pharma Inc. has taken an exclusive option to license DAX-044 from Melbourne, Australia-based Audax Biosciences, formerly Onko-innate, in a deal worth up to $1.34 billion, backing the ...
Idorsia Ltd. is branching into a new indication for its dual orexin 1 and 2 antagonist drug Quviviq (daridorexant), after a phase II pediatric insomnia trial showed unexpected improvements in the ...
AC Immune SA has reported new microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors potentially useful for the treatment of Alzheimer’s disease.
Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among children under 5 years, creating a major need for durable vaccines. The RSV fusion ...
Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results